Tirosint and Finasteride Interaction: Safety, Timing, and Monitoring

Tirosint is a liquid-filled gel capsule formulation of levothyroxine sodium, a synthetic thyroid hormone (T4) approved by the FDA for hypothyroidism. Its capsule contains fewer inactive ingredients (no dyes, gluten, or lactose) than standard levothyroxine tablets. Finasteride is a 5-alpha reductase type II inhibitor, sold as Propecia (1 mg, for androgenetic alopecia) and Proscar (5 mg, for benign prostatic hyperplasia). It works by blocking the conversion of testosterone to dihydrotestosterone (DHT).

No pharmacokinetic drug interaction between Tirosint and finasteride has been established in the FDA labeling for either product or in the pharmacology of either drug. They are cleared through different pathways: levothyroxine through hepatic and peripheral deiodination, glucuronidation, and sulfation, and finasteride mainly through hepatic oxidative metabolism. Neither drug is known to compete for the same transporters, displace the other from plasma proteins, or induce or inhibit an enzyme system the other depends on. This is a mechanism-based conclusion, not a finding from a dedicated interaction trial, because no such trial appears to exist in the published literature. The practical guidance that matters most for people on both drugs is the same guidance that applies to levothyroxine generally: take it consistently, on an empty stomach, separated from other oral medications and supplements.

Why this combination comes up so often

Hypothyroidism and androgenetic alopecia or BPH frequently occur in the same patients, especially as people age, so it is common for someone to be stabilized on Tirosint and then start finasteride, or the reverse. The clinical question people are really asking is usually one of two things: will finasteride disrupt my thyroid control, or will correcting my thyroid function change how finasteride works. Those are different questions with different answers.

What is established

• Finasteride is not listed as an interacting drug in the FDA prescribing information for Tirosint, and thyroid hormones are not listed as an interacting drug class in the FDA prescribing information for Proscar according to the FDA prescribing information for each product.
• Levothyroxine absorption is well documented to be affected by food, coffee, calcium and iron supplements, proton pump inhibitors, and bile acid sequestrants, through mechanisms unrelated to finasteride (gastric pH changes, chelation in the gut lumen, or altered gastric emptying). The exact magnitude of these effects varies across studies and should be verified against current literature rather than quoted as a fixed percentage.
• Finasteride's mechanism (5-alpha reductase inhibition) reduces circulating DHT; the FDA prescribing information for Proscar describes a substantial reduction in serum DHT with therapeutic dosing. This effect is independent of thyroid status.
• Thyroid hormone status is a recognized modifier of sex hormone-binding globulin (SHBG): hyperthyroidism raises SHBG and hypothyroidism lowers it, which changes free (unbound) testosterone even when total testosterone is unchanged. This is standard endocrine physiology, not specific to finasteride.

What is pharmacologically plausible but not established

Correcting undertreated hypothyroidism with Tirosint could raise SHBG toward normal, which would lower free testosterone and free DHT available at the tissue level. In theory this could act in the same direction as finasteride's anti-androgenic effect, or make it harder to tell how much of a treatment response belongs to which drug. This is a physiologic hypothesis based on how thyroid hormone and SHBG relate to each other generally. It has not been studied specifically in patients taking both Tirosint and finasteride, and the size of any such effect in a person whose TSH is only mildly abnormal is likely to be small. Clinicians should not attribute a change in hair loss trajectory or androgen symptoms to this crosstalk without first confirming thyroid status is actually improving or worsening.

What is not established

There is no published case series, cohort study, or interaction trial specifically evaluating levothyroxine (in any formulation) taken concurrently with finasteride. Absence of a reported interaction is consistent with the mechanistic reasoning above, but it is not the same as a study that specifically ruled one out. If a patient on this combination develops unexplained TSH drift or new symptoms, that should prompt standard thyroid work-up rather than an assumption that finasteride is or is not the cause.

Timing and administration

The core levothyroxine rule applies regardless of what else a patient takes: dose it consistently, on an empty stomach, and separate it from food and other oral medications by roughly 30 to 60 minutes at minimum. Finasteride's own absorption is not meaningfully affected by food, so it does not need to be timed around meals for its own sake. A simple daily pattern:

1. Take Tirosint first thing in the morning with water, before food or other pills.
2. Wait at least 30 minutes, then eat breakfast and take finasteride (with or without food).
3. If morning dosing is not realistic, levothyroxine can be moved to bedtime, dosed at least a few hours after the last meal; talk to the prescriber before changing the daily schedule, since consistency matters more than the specific time of day.

Calcium, iron, and proton pump inhibitors deserve a wider separation from Tirosint (commonly 4 hours, confirm with a pharmacist for the specific product) because these interact by a known mechanism. Finasteride does not carry that same absorption-interference risk, but keeping a standard buffer is a low-effort habit that protects against every other medication a patient might add later.

Monitoring when both drugs are prescribed

• Check TSH (and free T4 if the picture is unclear) before starting the second drug, so there is a baseline to compare against.
• Recheck TSH roughly 6 to 8 weeks after either drug is started or stopped. This interval is standard practice after any change to a levothyroxine regimen or to a patient's overall medication list; it is not specific evidence that finasteride affects thyroid hormone levels.
• If a patient reports a change in hair loss response, do not assume it reflects finasteride efficacy alone if thyroid status has also shifted recently; unresolved hypothyroidism causes diffuse hair thinning that can look like or overlap with androgenetic alopecia.
• SHBG or free testosterone testing is not routine here. Consider it only if there is a specific clinical question about androgen status that TSH and free T4 cannot answer on their own.

No dose adjustment of either drug is indicated based solely on co-prescription.

Evidence-status assessment: Tirosint plus finasteride

Clinicians and pharmacists reviewing this combination should verify current FDA labeling directly rather than relying on secondary summaries, and should treat any precise interaction statistic attributed to this specific pair as unverified until traced to a primary source.

When to seek clinician input rather than self-manage

• TSH moves outside the reference range without an obvious explanation (missed doses, new medication, weight change, pregnancy).
• New symptoms of thyroid over- or under-replacement appear after starting or stopping finasteride (palpitations, heat or cold intolerance, unexplained fatigue, rapid weight change).
• Finasteride is stopped after being used alongside Tirosint for androgen-related symptoms; DHT levels will rise, and any prior improvement attributed to combined thyroid correction and finasteride may partly reverse.
• Hair loss pattern changes in a way that suggests a cause other than androgenetic alopecia (patchy loss, scalp symptoms, rapid onset), which warrants dermatologic evaluation regardless of thyroid or finasteride status.

This is general education, not individualized dosing or diagnostic advice. Anyone changing either medication should do so with their prescriber, and thyroid function tests should be interpreted by the clinician managing that condition.

This article has not undergone qualified medical review and is pending that review. It is intended for general education and should not replace individualized guidance from the clinician or pharmacist managing a patient's thyroid replacement and finasteride therapy.